MedTrace Logo

The Protection Effect of Speeda® Rabies Vaccine for Human Use

NCT01827917 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2016-01-20

No results posted yet for this study

Summary

The objective of this study was to achieve the post-marketing protective effect research of Speeda® rabies vaccine for human use from Chengda Bio.

Conditions

  • Rabies Vaccine Allergy

Interventions

BIOLOGICAL

rabies vaccine

Injection on day 0、7、21

Sponsors & Collaborators

  • Beijing Center for Disease Control and Prevention

    lead OTHER_GOV

Principal Investigators

  • Nianmin Shi · Beijing Chaoyang District Centers for Disease Control and Prevention

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827917 on ClinicalTrials.gov